Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

Aileron Therapeutics, Inc. (NASDAQ:ALRN) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 35,300 shares, a growth of 7.0% from the March 15th total of 33,000 shares. Based on an average daily trading volume, of 39,200 shares, the short-interest ratio is presently 0.9 days. Approximately 0.9% of the shares of the stock are sold short.

Institutional Trading of Aileron Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Geode Capital Management LLC raised its stake in shares of Aileron Therapeutics by 23.2% in the 1st quarter. Geode Capital Management LLC now owns 54,799 shares of the company’s stock worth $68,000 after buying an additional 10,311 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Aileron Therapeutics by 65.5% in the 3rd quarter. Renaissance Technologies LLC now owns 190,691 shares of the company’s stock worth $39,000 after buying an additional 75,500 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Aileron Therapeutics by 52.9% during the third quarter. Envestnet Asset Management Inc. now owns 184,022 shares of the company’s stock worth $38,000 after purchasing an additional 63,651 shares during the period. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Aileron Therapeutics during the fourth quarter worth $48,000. Finally, Sigma Planning Corp acquired a new stake in shares of Aileron Therapeutics during the fourth quarter worth $51,000. Institutional investors own 90.89% of the company’s stock.

Aileron Therapeutics Price Performance

ALRN opened at $5.93 on Tuesday. Aileron Therapeutics has a one year low of $1.01 and a one year high of $7.12. The stock’s fifty day moving average is $5.38 and its 200-day moving average is $3.55.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.